28 results on '"Milazzo, Mark"'
Search Results
2. Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial
- Author
-
Ake, Julie A., Akapirat, Siriwat, Bose, Meera, Cale, Evan, Chan, Phillip, Chanthaburanun, Sararut, Churikanont, Nampueng, Dawson, Peter, Dumrongpisutikul, Netsiri, Getchalarat, Saowanit, Jongrakthaitae, Surat, Jongsakul, Krisada, Lerdlum, Sukalaya, Manasnayakorn, Sopark, McCullough, Corinne, Milazzo, Mark, Nuntapinit, Bessara, On, Kier, Ouellette, Madelaine, Phanuphak, Praphan, Sanders-Buell, Eric, Sangnoi, Nongluck, Shangguan, Shida, Sirivichayakul, Sunee, Tragonlugsana, Nipattra, Trichavaroj, Rapee, Ubolyam, Sasiwimol, Vasan, Sandhya, Wattanaboonyongcharoen, Phandee, Yamchuenpong, Thipvadee, Crowell, Trevor A, Colby, Donn J, Pinyakorn, Suteeraporn, Sacdalan, Carlo, Pagliuzza, Amélie, Intasan, Jintana, Benjapornpong, Khunthalee, Tangnaree, Kamonkan, Chomchey, Nitiya, Kroon, Eugène, de Souza, Mark S, Tovanabutra, Sodsai, Rolland, Morgane, Eller, Michael A, Paquin-Proulx, Dominic, Bolton, Diane L, Tokarev, Andrey, Thomas, Rasmi, Takata, Hiroshi, Trautmann, Lydie, Krebs, Shelly J, Modjarrad, Kayvon, McDermott, Adrian B, Bailer, Robert T, Doria-Rose, Nicole, Patel, Bijal, Gorelick, Robert J, Fullmer, Brandie A, Schuetz, Alexandra, Grandin, Pornsuk V, O'Connell, Robert J, Ledgerwood, Julie E, Graham, Barney S, Tressler, Randall, Mascola, John R, Chomont, Nicolas, Michael, Nelson L, Robb, Merlin L, Phanuphak, Nittaya, and Ananworanich, Jintanat
- Published
- 2019
- Full Text
- View/download PDF
3. Next-generation sequencing of HIV-1 single genome amplicons
- Author
-
Kijak, Gustavo H., Sanders-Buell, Eric, Pham, Phuc, Harbolick, Elizabeth A., Oropeza, Celina, O’Sullivan, Anne Marie, Bose, Meera, Beckett, Charmagne G., Milazzo, Mark, Robb, Merlin L., Peel, Sheila A., Scott, Paul T., Michael, Nelson L., Armstrong, Adam W., Kim, Jerome H., Brett-Major, David M., and Tovanabutra, Sodsai
- Published
- 2019
- Full Text
- View/download PDF
4. Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost
- Author
-
Ake, Julie A., Schuetz, Alexandra, Pegu, Poonam, Wieczorek, Lindsay, Eller, Michael A., Kibuuka, Hannah, Sawe, Fredrick, Maboko, Leonard, Polonis, Victoria, Karasavva, Nicos, Weiner, David, Sekiziyivu, Arthur, Kosgei, Josphat, Missanga, Marco, Kroidl, Arne, Mann, Philipp, Ratto-Kim, Silvia, Eller, Leigh Anne, Earl, Patricia, Moss, Bernard, Dorsey-Spitz, Julie, Milazzo, Mark, Ouedraogo, G. Laissa, Rizvi, Farrukh, Yan, Jian, Khan, Amir S., Peel, Sheila, Sardesai, Niranjan Y., Michael, Nelson L., Ngauy, Viseth, Marovich, Mary, and Robb, Merlin L.
- Published
- 2017
5. HIV prevalence and awareness among adults presenting for enrolment into a study of people at risk for HIV in Kisumu County, Western Kenya.
- Author
-
Sing'oei, Valentine, Nwoga, Chiaka, Yates, Adam, Owuoth, John, Otieno, June, Broach, Erica, Li, Qun, Hassen, Zebiba, Imbach, Michelle, Milazzo, Mark, Mebrahtu, Tsedal, Robb, Merlin L., Ake, Julie A., Polyak, Christina S., and Crowell, Trevor A.
- Subjects
HIV ,DIAGNOSIS of HIV infections ,HIV infection transmission ,AT-risk people ,HIV prevention ,POISSON regression - Abstract
Introduction: Despite declines in new HIV diagnoses both globally and in Kenya, parts of Western Kenya still report high HIV prevalence and incidence. We evaluated HIV prevalence to inform the development of policies for strategic and targeted HIV prevention interventions. Methods: Adult participants aged 18–35 years were recruited in Kisumu County and screened for HIV for a prospective HIV incidence cohort. Questionnaires assessed HIV-associated risk behaviors. Participants who tested positive for HIV were disaggregated into groups based on prior knowledge of their HIV status: previously-diagnosed and newly-diagnosed. In separate analyses by prior knowledge, robust Poisson regression was used to estimate prevalence ratios (PRs) and 95% confidence intervals (CIs) for factors potentially associated with a positive HIV test in each group, as compared to participants without HIV. Results: Of 1059 participants tested for HIV, 196 (18.5%) had a positive HIV test. Among PLWH, 78 (39.8%) were newly diagnosed with HIV at screening. After adjusting for other variables, previously-diagnosed HIV was more common among females than males (PR 2.70, 95%CI 1.69–4.28), but there was no observed sex difference in newly-diagnosed HIV prevalence (PR 1.05, 95%CI 0.65–1.69). Previously-diagnosed HIV was also more common among people reporting consistent use of condoms with primary sexual partners as compared to inconsistent condom use (PR 3.19, 95%CI 2.09–4.86), but newly-diagnosed HIV was not associated with such a difference between consistent and inconsistent condom use (PR 0.73, 95%CI 0.25–2.10). Conclusion: Prevalence of newly-diagnosed HIV was high, at approximately 8% of participants, and not statistically different between genders, highlighting the need for improved HIV case finding regardless of sex. The higher prevalence of previously-diagnosed HIV in female participants may reflect higher rates of HIV testing through more encounters with the healthcare system. Higher prevalence of consistent condom use amongst those previously-diagnosed suggests behavioral change to reduce HIV transmission, a potential benefit of policies to facilitate earlier HIV diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. New Subtype B Containing HIV-1 Circulating Recombinant of sub-Saharan Africa Origin in Nigerian Men Who Have Sex With Men
- Author
-
Billings, Erik, Kijak, Gustavo H., Sanders-Buell, Eric, Ndembi, Nicaise, OʼSullivan, Anne Marie, Adebajo, Sylvia, Kokogho, Afoke, Milazzo, Mark, Lombardi, Kara, Baral, Stefan, Nowak, Rebecca, Ramadhani, Habib, Gramzinski, Robert, Robb, Merlin L., Michael, Nelson L., Charurat, Manhattan E., Ake, Julie, Crowell, Trevor A., and Tovanabutra, Sodsai
- Published
- 2019
- Full Text
- View/download PDF
7. HIV Type 1 Disease Progression to AIDS and Death in a Rural Ugandan Cohort Is Primarily Dependent on Viral Load Despite Variable Subtype and T-Cell Immune Activation Levels
- Author
-
Eller, Michael A., Opollo, Marc S., Liu, Michelle, Redd, Andrew D., Eller, Leigh Anne, Kityo, Cissy, Kayiwa, Joshua, Laeyendecker, Oliver, Wawer, Maria J., Milazzo, Mark, Kiwanuka, Noah, Gray, Ronald H., Serwadda, David, Sewankambo, Nelson K., Quinn, Thomas, Michael, Nelson L., Wabwire-Mangen, Fred, Sandberg, Johan K., and Robb, Merlin L.
- Published
- 2015
8. Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand
- Author
-
Robb, Merlin L., Eller, Leigh A., Kibuuka, Hannah, Rono, Kathleen, Maganga, Lucas, Nitayaphan, Sorachai, Kroon, Eugene, Sawe, Fred K., Sinei, Samuel, Sriplienchan, Somchai, Jagodzinski, Linda L., Malia, Jennifer, Manak, Mark, de Souza, Mark S., Tovanabutra, Sodsai, Sanders-Buell, Eric, Rolland, Morgane, Dorsey-Spitz, Julie, Eller, Michael A., Milazzo, Mark, Li, Qun, Lewandowski, Andrew, Wu, Hao, Swann, Edith, OʼConnell, Robert J., Peel, Sheila, Dawson, Peter, Kim, Jerome H., and Michael, Nelson L.
- Published
- 2016
- Full Text
- View/download PDF
9. Prospective screening for sexually transmitted infections among US service members with Chlamydia trachomatis or Neisseria gonorrhoeae infection.
- Author
-
Bedno, Sheryl, Hakre, Shilpa, Clark, Shannon, Dear, Nicole, Milazzo, Mark, McCoart, Amy, Hassen, Zebiba, Liu, Heather, Bianchi, Elizabeth J., Darden, Janice M., Paudel, Misti, Malia, Jennifer A., Peel, Sheila A., Scott, Paul T., and Petruccelli, Bruno
- Subjects
SEXUALLY transmitted diseases ,NEISSERIA gonorrhoeae ,CHLAMYDIA trachomatis ,MILITARY personnel ,MEDICAL screening ,CHLAMYDIA ,NEISSERIA - Abstract
Background: Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are the most common bacterial causes of sexually transmitted infection (STI) in the United States (US). The purpose of this study was to determine the frequency of reinfection during a six-month study period and to evaluate the retesting interval for those infected with CT or NG. Methods: We conducted a prospective, six-month follow-up study among US military personnel with new onset, laboratory-confirmed CT or NG, recruited from an STI clinic at a large military base from January 2018 to January 2020. Each participant was randomly assigned to one of four groups, which differed only by the timing of the first study-associated follow-up visit after CT or NG diagnosis. Results: Of the 347 initially recruited into the study, 267 participants completed a follow-up visit prior to their scheduled, final visit 6 months after initial infection. The median age at enrollment was 22 years and 41.0% were female. There were 32 (12.0%) reinfections (30 CT and 2 NG) after treatment of an index diagnosis of CT or NG within the six-month study period. Six of the CT reinfections were only detected at the final visit. A review of medical records revealed additional CT and NG reinfections. The probability of detecting a reinfection did not vary significantly by timing of follow-up. Conclusions: The likelihood of detecting CT or NG reinfection did not differ according to time of follow up visit among study participants, thus supporting CDC guidance to retest three months post treatment. Efforts should continue to focus on STI prevention and risk reduction. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the Clinical Efficacy of Resistance Testing Trial
- Author
-
Wegner, Scott A., Wallace, Mark R., Aronson, Naomi E., Tasker, Sybil A., Blazes, David L., Tamminga, Cindy, Fraser, Susan, Dolan, Matthew J., Stephan, Kevin T., Michael, Nelson L., Jagodzinski, Linda L., Vahey, Maryanne T., Gilcrest, Joyce L., Tracy, LaRee, Milazzo, Mark J., Murphy, Daniel J., McKenna, Paula, Hertogs, Kurt, Rinehart, Alex, Larder, Brendan, and Birx, Deborah L.
- Subjects
Health ,Health care industry - Published
- 2004
11. Routine HIV clinic visit adherence in the African Cohort Study.
- Author
-
Dear, Nicole, Esber, Allahna, Iroezindu, Michael, Bahemana, Emmanuel, Kibuuka, Hannah, Maswai, Jonah, Owuoth, John, Polyak, Christina S., Ake, Julie A., Crowell, Trevor A., the AFRICOS Study Group, Bartolanzo, Danielle, Reynolds, Alexus, Song, Katherine, Milazzo, Mark, Francisco, Leilani, Mankiewicz, Shauna, Schech, Steven, Golway, Alexandra, and Omar, Badryah
- Subjects
HIV-positive persons ,CONFIDENCE intervals ,SELF-evaluation ,VIRAL load ,RISK assessment ,SOCIOECONOMIC factors ,HIGHLY active antiretroviral therapy ,TREATMENT effectiveness ,QUESTIONNAIRES ,CD4 lymphocyte count ,PATIENT compliance ,MEDICAL appointments ,LOGISTIC regression analysis ,ODDS ratio ,SUB-Saharan Africans ,LONGITUDINAL method - Abstract
Background: Retention in clinical care is important for people living with HIV (PLWH). Evidence suggests that missed clinic visits are associated with interruptions in antiretroviral therapy (ART), lower CD4 counts, virologic failure, and overlooked coinfections. We identified factors associated with missed routine clinic visits in the African Cohort Study (AFRICOS). Methods: In 2013, AFRICOS began enrolling people with and without HIV in Uganda, Kenya, Tanzania, and Nigeria. At enrollment and every 6 months thereafter, sociodemographic questionnaires are administered and clinical outcomes assessed. Missed clinic visits were measured as the self-reported number of clinic visits missed in the past 6 months and dichotomized into none or one or more visits missed. Logistic regression with generalized estimating equations was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for associations between risk factors and missed visits. Results: Between January 2013 and March 2020, 2937 PLWH were enrolled, of whom 2807 (95.6%) had initiated ART and 2771 had complete data available for analyses. Compared to PLWH 50+, missed clinic visits were more common among those 18–29 years (aOR 2.33, 95% CI 1.65–3.29), 30–39 years (aOR 1.59, 95% CI 1.19–2.13), and 40–49 years (aOR 1.42, 95% CI 1.07–1.89). As compared to PLWH on ART for < 2 years, those on ART for 4+ years were less likely to have missed clinic visits (aOR 0.72, 95% CI 0.55–0.95). Missed clinic visits were associated with alcohol use (aOR 1.34, 95% CI 1.05–1.70), a history of incarceration (aOR 1.42, 95% CI 1.07–1.88), depression (aOR 1.47, 95% CI 1.13–1.91), and viral non-suppression (aOR 2.50, 95% CI 2.00–3.12). As compared to PLWH who did not miss any ART in the past month, missed clinic visits were more common among those who missed 1–2 days (aOR 2.09, 95% CI 1.65–2.64) and 3+ days of ART (aOR 7.06, 95% CI 5.43–9.19). Conclusions: Inconsistent clinic attendance is associated with worsened HIV-related outcomes. Strategies to improve visit adherence are especially needed for young PLWH and those with depression. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. Young at risk-people in Maputo City, Mozambique, present a high willingness to participate in HIV trials: Results from an HIV vaccine preparedness cohort study.
- Author
-
Capitine, Igor P. U., Macicame, Ivalda B., Uanela, Artur M., Bhatt, Nilesh B., Yates, Adam, Milazzo, Mark, Nwoga, Chiaka, Crowell, Trevor A., Michael, Nelson L., Robb, Merlin L., Jani, Ilesh V., Kroidl, Arne, Polyak, Christina S., and De Schacht, Caroline
- Subjects
AIDS vaccines ,VACCINE trials ,HUMAN sexuality ,GENERALIZED estimating equations ,LOGISTIC regression analysis ,HIV infections ,HIV - Abstract
Introduction: Vaccine efficacy testing requires engagement of willing volunteers with high disease incidence. We evaluated factors associated with willingness to participate in potential future HIV vaccine trials in Maputo, Mozambique. Methods: Adults aged 18–35 years without HIV and who reported at least two sexual partners in the 3 months prior to screening were enrolled into a 24-month observational study. They were asked at screening and exit if they would be willing to participate in a theoretical HIV vaccine study. Bivariate and multivariate logistic regression analyses were done between willingness to participate, demographic, sexual behavior, and motivational factors for screening visit data. Logistic regression with generalized estimating equations (GEE) was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for factors potentially associated with willingness to participate for data from both visits. Results: A total of 577 participants without HIV were eligible, including 275 (48%) women. The mean age was 22.2 (SD ± 3.9) years. At screening 529 (92%) expressed willingness to participate and the proportion remained stable at 378 (88%) of the 430 participants retained through the exit visit (p = 0.209). Helping the country (n = 556) and fear of needles (n = 26) were the top motive and barrier for willingness to participate, respectively. Results from the GEE binary logistic regression (screening visit and exit visit) showed that wanting to learn how to avoid risk behaviors (aOR 3.33, 95% CI: 1.61–6.86) and feeling protected against HIV infection (aOR 2.24, 95% CI: 1.07–4.7) were associated with willingness to participate in HIV vaccine studies. Conclusion: The majority of our study population in Mozambique expressed willingness to participate in a theoretical HIV vaccine trial. Participation in a HIV vaccine trial was seen as a way to contribute to the fight against HIV but was associated with some unrealistic expectations such as protection against HIV. This reinforces the need for continuous mobilization and awareness of potential participants to HIV vaccine trial. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. Effectiveness of highly-active antiretroviral therapy by race/ethnicity
- Author
-
Silverberg, Michael J, Wegner, Scott A, Milazzo, Mark J, McKaig, Rosemary G, Williams, Carolyn F, Agan, Brian K, Armstrong, Adam W, Gange, Stephen J, Hawkes, Clifton, OʼConnell, Robert J, Ahuja, Sunil K, and Dolan, Matthew J
- Published
- 2006
- Full Text
- View/download PDF
14. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals
- Author
-
Burgi, Alina, Brodine, Stephanie, Wegner, Scott, Milazzo, Mark, Wallace, Mark R., Spooner, Katherine, Blazes, David L., Agan, Brian K., Armstrong, Adam, Fraser, Susan, and Crum, Nancy F.
- Published
- 2005
- Full Text
- View/download PDF
15. Prevalence and risk factors associated with HIV and syphilis co-infection in the African Cohort Study: a cross-sectional study.
- Author
-
Gilbert, Laura, Dear, Nicole, Esber, Allahna, Iroezindu, Michael, Bahemana, Emmanuel, Kibuuka, Hannah, Owuoth, John, Maswai, Jonah, Crowell, Trevor A., Polyak, Christina S., Ake, Julie A., the AFRICOS Study Group, Bartolanzo, Danielle, Reynolds, Alexus, Song, Katherine, Milazzo, Mark, Francisco, Leilani, Mankiewicz, Shauna, Schech, Steven, and Golway, Alexandra
- Subjects
SYPHILIS ,MIXED infections ,HIV-positive persons ,AFRICANA studies ,CROSS-sectional method ,HIV - Abstract
Background: Each year, 5.6 million new syphilis cases are diagnosed globally. Guidelines for people living with HIV (PLWH) in low-income countries (LIC) recommend STI testing for symptomatic persons and those newly diagnosed with HIV; routine STI testing is less clear. Here we provide updated syphilis prevalence and identify co-infection risk factors in PLWH in the African Cohort Study (AFRICOS) to understand these rates as they relate to syndromic treatment.Methods: AFRICOS is a study enrolling PLWH and HIV-uninfected individuals in four African countries. Participant study enrollment information was used to determine syphilis prevalence and co-infection risk factors. Inclusion criteria consisted of adults 18 years or older receiving care at a participating clinic as a long-term resident who consented to data and specimen collection. Exclusion criteria consisted of pregnancy and/or imprisonment. Screen-positive syphilis was defined as a reactive rapid plasma regain (RPR) upon study enrollment whereas confirmed syphilis included a reactive RPR followed by reactive treponemal test. Multivariate analyses was performed to determine HIV and syphilis co-infection risk factors.Results: Between 2013 and March 1, 2020, 2939 PLWH enrolled and 2818 were included for analysis. Screen-positive and confirmed syphilis prevalence were 5.3% (151/2818) and 3.1% (87/2818), respectively. When the analysis was restricted to PLWH with an RPR titer of greater than, or equal to, 1:8, 11/87 (12.6%) participants were included. No PLWH and confirmed syphilis had documented genital ulcers. In the multivariate model, participants with confirmed syphilis co-infection were more likely to have none or some primary education [aOR 3.29 (1.60, 6.74)] and consume alcohol [aOR 1.87 (1.16, 3.03)] compared to those without syphilis. Antiretroviral therapy (ART) with suppressed viral load (VL) was protective in the unadjusted model but not adjusted multivariate model.Conclusions: Our findings show that syphilis rates in sub-Saharan Africa remain elevated where diagnosis remains challenging, and that both lower education level and alcohol consumption are significantly associated with HIV/syphilis co-infection in AFRICOS. Based on our analysis, current STI guidelines targeting testing for African individuals with either new HIV diagnosis or syndromic symptoms may be inadequate, highlighting the need for increased testing and treatment strategies in resource-limited settings. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
16. HIV-1 seroconversion in United States Army active duty personnel, 1985–1999
- Author
-
Renzullo, Philip O., Sateren, Warren B., Garner, Robin P., Milazzo, Mark J., Birx, Deborah L., and McNeil, John G.
- Published
- 2001
17. Assessing the impact of HIV support groups on antiretroviral therapy adherence and viral suppression in the African cohort study.
- Author
-
Mbah, Prudence, Iroezindu, Michael, Esber, Allahna L., Dear, Nicole, Reed, Domonique, Adamu, Yakubu, Tiamiyu, Abdulwasiu Bolaji, Mohammed, Samirah Sani, Kibuuka, Hannah, Maswai, Jonah, Owuoth, John, Bahemana, Emmanuel, Ake, Julie A., Polyak, Christina S., Crowell, Trevor A., for the AFRICOS Study Group, Bartolanzo, Danielle, Reynolds, Alexus, Song, Katherine, and Milazzo, Mark
- Subjects
SUPPORT groups ,GROUP psychotherapy ,ANTIRETROVIRAL agents ,HIV-positive persons ,GENERALIZED estimating equations - Abstract
Background: Support groups for people living with HIV (PLWH) may improve HIV care adherence and outcomes. We assessed the impact of support group attendance on antiretroviral therapy (ART) adherence and viral suppression in four African countries. Methods: The ongoing African Cohort Study (AFRICOS) enrolls participants at 12 clinics in Kenya, Uganda, Tanzania, and Nigeria. Self-reported attendance of any support group meetings, self-reported ART adherence, and HIV RNA are assessed every 6 months. Logistic regression models with generalized estimating equations were used to estimate adjusted odds ratios (aORs) and 95% confidence intervals (95% CIs) for support group attendance and other factors potentially associated with ART adherence and viral suppression. Results: From January 2013 to December 1, 2019, 1959 ART-experienced PLWH were enrolled and 320 (16.3%) reported any support group attendance prior to enrollment. Complete ART adherence, with no missed doses in the last 30 days, was reported by 87.8% while 92.4% had viral suppression <1000copies/mL across all available visits. There was no association between support group attendance and ART adherence in unadjusted (OR 1.01, 95% CI 0.99–1.03) or adjusted analyses (aOR 1.00, 95% CI 0.98–1.02). Compared to PLWH who did not report support group attendance, those who did had similar odds of viral suppression in unadjusted (OR 0.99, 95% CI 0.978–1.01) and adjusted analyses (aOR 0.99, 95% CI 0.97–1.01). Conclusion: Support group attendance was not associated with significantly improved ART adherence or viral suppression, although low support group uptake may have limited our ability to detect a statistically significant impact. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
18. Factors associated with sexually transmitted infections among care-seeking adults in the African Cohort Study.
- Author
-
Semwogerere, Michael, Dear, Nicole, Tunnage, Joshua, Reed, Domonique, Kibuuka, Hannah, Kiweewa, Francis, Iroezindu, Michael, Bahemana, Emmanuel, Maswai, Jonah, Owuoth, John, Crowell, Trevor A., Ake, Julie A., Polyak, Christina S., Esber, Allahna, for the AFRICOS Study Group, Bartolanzo, Danielle, Reynolds, Alexus, Song, Katherine, Milazzo, Mark, and Francisco, Leilani
- Subjects
SEXUALLY transmitted diseases ,HIV-positive persons ,SEXUALLY transmitted disease diagnosis ,DISEASE prevalence ,MENTAL health - Abstract
Objectives: Sexually transmitted infections (STIs) are a major cause of morbidity. Understanding drivers of transmission can inform effective prevention programs. We describe STI prevalence and identify factors associated with STIs in four African countries.Methods: The African Cohort Study is an ongoing, prospective cohort in Kenya, Nigeria, Tanzania and Uganda. At enrollment, a physical exam was conducted and STI diagnosis made by a clinician using a syndromic management approach. Multivariable logistic regression was used to estimate adjusted odds ratios (aORs) and 95% confidence intervals (95% CIs) for factors associated with an STI diagnosis.Results: As of June 2020, 3544 participants were enrolled. STI prevalence was 7.7% and did not differ by HIV status (p = 0.30). Prevalence differed by syndrome (3.5% vaginal discharge, 1.5% genital ulcer, 2.1% lower abdominal pain, 0.2% inguinal bubo). The odds of having an STI were higher at all sites compared to Kisumu West, Kenya, and among those with a primary level education or below compared to those with secondary or higher (aOR: 1.77; 95% CI: 1.32-2.38). The odds of an STI diagnosis was higher among participants 18-29 years (aOR: 2.29; 95% CI: 1.35-3.87), females (aOR: 2.64; 95% CI: 1.94-3.59), and those with depression (aOR: 1.78; 95% CI: 1.32-2.38). Among PLWH, similar factors were independently associated with an STI diagnosis. Viral suppression was protective against STIs (aOR: 2.05; 95% CI: 1.32-3.20).Conclusions: Prevalence of STIs varied by site with young people and females most at risk for STIs. Mental health is a potential target area for intervention. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
19. Determining hematological, biochemical and immunological reference values in healthy adults with high-risk for HIV acquisition in Mozambique.
- Author
-
Cumbane, Victória, Imbach, Michelle, Chissumba, Raquel Matavele, Macicame, Ivalda, Eller, Leigh Anne, Lawlor, John, Milazzo, Mark, Li, Qun, Crowell, Trevor, Mutombene, Mirna, Guiliche, Onélia, Viegas, Edna, Nwoga, Chiaka, Yates, Adam, Michael, Nelson, Robb, Merlin, Polyak, Christina S., Jani, Ilesh V., and Bhatt, Nilesh
- Subjects
REFERENCE values ,LEUCOCYTES ,BLOOD cell count ,HIV ,HEPATITIS B virus ,ADULTS - Abstract
Introduction: In many African countries, laboratory reference values are not established for the local healthy adult population. In Mozambique, reference values are known for young adults (18-24yo) but not yet established for a wider age range. Our study aimed to establish hematological, biochemical and immunological reference values for vaccine trials in Mozambican healthy adults with high-risk for HIV acquisition. Methods: A longitudinal cohort and site development study in Mozambique between November 2013 and 2014 enrolled 505 participants between 18 to 35 years old. Samples from these healthy participants, were analyzed to determine reference values. All volunteers included in the analysis were clinically healthy and human immunodeficiency virus (HIV), hepatitis B and C virus, and syphilis negative. Median and reference ranges were calculated for the hematological, biochemical and immunological parameters. Ranges were compared with other African countries, the USA and the US National Institute of Health (NIH) Division of AIDS (DAIDS) toxicity tables. Results: A total of 505 participant samples were analyzed. Of these, 419 participants were HIV, hepatitis B and C virus and syphilis negative including 203 (48.5%) females and 216 (51.5%) males, with a mean age of 21 years. In the hematological parameters, we found significant differences between sex for erythrocytes, hemoglobin, hematocrit, MCV, MCH and MCHC as well as white blood cells, neutrophils and platelets: males had higher values than females. There were also significant differences in CD4
+ T cell values, 803 cells/μL in men versus 926 cells/μL in women. In biochemical parameters, men presented higher values than women for the metabolic, enzymatic and renal parameters: total and direct bilirubin, ALT and creatinine. Conclusion: This study has established reference values for healthy adults with high-risk for HIV acquisition in Mozambique. These data are helpful in the context of future clinical research and patient care and treatment for the general adult population in the Mozambique and underline the importance of region-specific clinical reference ranges. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
20. Look-Back Investigation after Human Immunodeficiency Virus Seroconversion in a Pediatric Dentist
- Author
-
Longfield, Jenice N., Brundage, John, Badger, Gary, Vire, Donald, Milazzo, Mark, Ray, Karen, Gemmill, Robert, Magruder, Charles, Oster, Charles N., and Roberts, Chester
- Published
- 1994
21. HIV prevalence and risk behavior among male and female adults screened for enrolment into a vaccine preparedness study in Maputo, Mozambique.
- Author
-
Macicame, Ivalda, Bhatt, Nilesh, Matavele Chissumba, Raquel, Eller, Leigh Anne, Viegas, Edna, Araújo, Khelvon, Nwoga, Chiaka, Li, Qun, Milazzo, Mark, Hills, Nancy K., Lindan, Christina, Michael, Nelson L., Robb, Merlin L., Jani, Ilesh, and Polyak, Christina S.
- Subjects
RISK-taking behavior ,SEXUALLY transmitted diseases ,HIV infections ,HIV ,AIDS vaccines ,PREPAREDNESS ,SELF-perception - Abstract
Introduction: Mozambique continues to have a significant burden of HIV. Developing strategies to control the HIV epidemic remains a key priority for the Mozambican public health community. The primary aim of this study was to determine HIV prevalence and risk behavior among males and females screened for a HIV vaccine preparedness study in Maputo, Mozambique. Methods: Male and female participants between 18–35 years old were recruited from the general community and from female sex worker (FSW) and lesbian, gay, bisexual, and transgender (LGBT) associations in Maputo. All participants were screened for HIV and a questionnaire was administered to each participant to assess HIV risk behavior. Results: A total of 1125 adults were screened for HIV infection, among whom 506 (45%) were male. Among men, 5.7% reported having had sex with men (MSM) and 12% of female participants reported having exchanged sex for money, goods or favors in the past 3 months. The overall HIV prevalence was 10.4%; 10.7% of women, and 10.1% of men were HIV infected; 41.4% of MSM were seropositive. HIV infection was associated with older age (25–35 years old) (OR: 6.13, 95% CI: 3.01, 12.5), MSM (OR: 9.07, 95% CI: 3.85, 21.4), self-perception of being at high-risk for HIV (OR: 3.99, 95% CI: 1.27, 12.5) and self-report of a history of a diagnosis of sexually transmitted infection (OR: 3.75, 95% CI: 1.57, 8.98). Conclusion: In our cohort, HIV prevalence was much higher among MSM compared to the overall prevalence. Behavioral factors were found to be more associated with HIV prevalence than demographic factors. The study findings demonstrate the critical importance of directing services to minority communities, such as MSM, when prevention strategies are being devised for the general population. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
22. Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques.
- Author
-
McCracken, Michael K., Gromowski, Gregory D., Friberg, Heather L., Lin, Xiaoxu, Abbink, Peter, De La Barrera, Rafael, Eckles, Kenneth H., Garver, Lindsey S., Boyd, Michael, Jetton, David, Barouch, Dan H., Wise, Matthew C., Lewis, Bridget S., Currier, Jeffrey R., Modjarrad, Kayvon, Milazzo, Mark, Liu, Michelle, Mullins, Anna B., Putnak, J. Robert, and Michael, Nelson L.
- Subjects
ZIKA virus infections ,MEDICAL microbiology ,CERCOPITHECIDAE ,ETIOLOGY of diseases ,IMMUNITY - Abstract
Studies have demonstrated cross-reactivity of anti-dengue virus (DENV) antibodies in human sera against Zika virus (ZIKV), promoting increased ZIKV infection in vitro. However, the correlation between in vitro and in vivo findings is not well characterized. Thus, we evaluated the impact of heterotypic flavivirus immunity on ZIKV titers in biofluids of rhesus macaques. Animals previously infected (≥420 days) with DENV2, DENV4, or yellow fever virus were compared to flavivirus-naïve animals following infection with a Brazilian ZIKV strain. Sera from DENV-immune macaques demonstrated cross-reactivity with ZIKV by antibody-binding and neutralization assays prior to ZIKV infection, and promoted increased ZIKV infection in cell culture assays. Despite these findings, no significant differences between flavivirus-naïve and immune animals were observed in viral titers, neutralizing antibody levels, or immune cell kinetics following ZIKV infection. These results indicate that prior infection with heterologous flaviviruses neither conferred protection nor increased observed ZIKV titers in this non-human primate ZIKV infection model. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
23. An Evaluation of Selected Populations for HIV-1 Vaccine Cohort Development in Nigeria.
- Author
-
Njoku, Ogbonnaya S., Manak, Mark M., O’Connell, Robert J., Shutt, Ashley L. W., Malia, Jennifer A., JrHeipertz, Richard A., Tovanabutra, Sodsai, Milazzo, Mark J., Akintunde, Gideon Akindiran, Alabi, Abraham S., Suleiman, Aminu, Ogundeji, Amos A., Kene, Terfa S., Nelson, Robbie, Ayemoba, Ojor R., Singer, Darrell E., Robb, Merlin L., Peel, Sheila A., and Michael, Nelson L.
- Subjects
AIDS diagnosis ,AIDS vaccines ,WESTERN immunoblotting ,DISEASE prevalence - Abstract
Development of a globally effective HIV-1 vaccine will need to encompass Nigeria, one of the hardest hit areas, with an estimated 3.2 million people living with HIV. This cross-sectional Institutional Review Board (IRB) approved study was conducted in 2009–12 at four market sites and two highway settlements sites in Nigeria to identify and characterize populations at high risk for HIV; engage support of local stakeholders; and assess the level of interest in future vaccine studies. Demographic, HIV risk data were collected by structured interviewer-administered questionnaires. Blood samples were tested on site by HIV rapid diagnostic tests, followed by rigorous confirmatory testing, subtype evaluation and testing for HBV and HCV markers in a clinical reference laboratory. Of 3229 study participants, 326 were HIV infected as confirmed by Western Blot or RNA, with a HIV prevalence of 15.4%-23.9% at highway settlements and 3.1%-9.1% at market sites. There was no observable correlation of prevalence of HIV-1 (10.1%) with HBV (10.9%) or HCV (2.9%). Major HIV-1 subtypes included CRF02_AG (37.5%); G (27.5%); G/CRF02_AG (25.9%); and non-typeable (8.9%), with 0.3% HIV-2. Univariate analysis found age, gender, marital status, level of education, and sex under substance influence as significant risk factors for HIV (p<0.001). Educating and winning the trust of local community leadership ensured high level of participation (53.3–77.9%) and willingness to participate in future studies (95%). The high HIV prevalence and high risk of HIV infection at highway settlement and mammy markets make them well suited for targeting future vaccine trials in Nigeria. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
24. Phase I Study of Safety and Immunogenicity of an Escherichia coli-Derived Recombinant Protective Antigen (rPA) Vaccine to Prevent Anthrax in Adults.
- Author
-
Brown, Bruce K., Cox, Josephine, Gillis, Anita, VanCott, Thomas C., Marovich, Mary, Milazzo, Mark, Antonille, Tanya Santelli, Wieczorek, Lindsay, McKee Jr., Kelly T., Metcalfe, Karen, Mallory, Raburn M., Birx, Deborah, Polonis, Victoria R., and Robb, Merlin L.
- Subjects
ESCHERICHIA coli ,ANTHRAX ,MEDICAL experimentation on humans ,BACILLUS anthracis ,IMMUNE response ,CLINICAL trials ,IMMUNOGLOBULINS ,GEOMETRIC measure theory ,PLACEBOS - Abstract
Background: The fatal disease caused by Bacillus anthracis is preventable with a prophylactic vaccine. The currently available anthrax vaccine requires a lengthy immunization schedule, and simpler and more immunogenic options for protection against anthrax are a priority for development. In this report we describe a phase I clinical trial testing the safety and immunogenicity of an anthrax vaccine using recombinant Escherichia coli-derived, B. anthracis protective antigen (rPA). Methodology/Principal Findings: A total of 73 healthy adults ages 18-40 were enrolled and 67 received 2 injections separated by 4 weeks of either buffered saline placebo, or rPA formulated with or without 704 μg/ml Alhydrogel® adjuvant in increasing doses (5, 25, 50, 100 μg) of rPA. Participants were followed for one year and safety and immunologic data were assessed. Tenderness and warmth were the most common post-injection site reactions. No serious adverse events related to the vaccine were observed. The most robust humoral immune responses were observed in subjects receiving 50 mg of rPA formulated with Alhydrogel® with a geometric mean concentration of anti-rPA IgG antibodies of 283 μg/ml and a toxin neutralizing geometric 50% reciprocal geometric mean titer of 1061. The highest lymphoproliferative peak cellular response (median Lymphocyte Stimulation Index of 29) was observed in the group receiving 25 μg Alhydrogel®-formulated rPA. Conclusions/Significance: The vaccine was safe, well tolerated and stimulated a robust humoral and cellular response after two doses. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
25. Predictors of HIV-1 Disease Progression in Early- and Late-Stage Patients.
- Author
-
Gardner Jr., Lytt I., Brundage, John F., McNeil, John G., Milazzo, Mark J., Redfield, Robert R., Aronson, Naomi E., Craig, D. Baxter, Davis, Charles, Gates, Robert H., Levin, Lynn I., Michael, Rodney A., Oster, Charles N., Ryan, William C., Burke, Donald S., and Tramont, Edmund C.
- Published
- 1992
26. Emergence of Individual HIV-Specific CD8 T Cell Responses during Primary HIV-1 Infection Can Determine Long-Term Disease Outcome.
- Author
-
Streeck, Hendrik, Richard Lu, Beckwith, Noor, Milazzo, Mark, Liu, Michelle, Routy, Jean-Pierre, Little, Susan, Jessen, Heiko, Kelleher, Anthony D., Hecht, Frederick, Sekaly, Rafick-Pierre, Alter, Galit, Heckerman, David, Carrington, Mary, Rosenberg, Eric S., and Altfeld, Marcus
- Subjects
- *
HIV infections -- Immunological aspects , *CD8 antigen , *IMMUNE response , *ANTIVIRAL agents , *HEALTH outcome assessment - Abstract
Events during primary HIV-1 infection have been shown to be critical for the subsequent rate of disease progression. Early control of viral replication, resolution of clinical symptoms and development of a viral set point have been associated with the emergence of HIV-specific CD8 T cell responses. Here we assessed which particular HIV-specific CD8 T cell responses contribute to long-term control of HIV-1. A total of 620 individuals with primary HIV-1 infection were screened by gamma interferon (IFN-γ) enzyme-linked immunospot (ELISPOT) assay for HLA class I-restricted, epitope-specific CD8 T cell responses using optimally defined epitopes approximately 2 months after initial presentation. The cohort was predominantly male (97%) and Caucasian (83%) (Fiebig stages II/III [n = 157], IV [n = 64], V [n = 286], and VI [n = 88] and Fiebig stage not determined [n25]). Longitudinal viral loads, CD4 count, and time to ART were collected for all patients. We observed strong associations between viral load at baseline (initial viremia) and the established early viral set points (P<0.0001). Both were significantly associated with HLA class I genotypes (P< 0.0009). While neither the breadth nor the magnitude of HIV-specific CD8 T cell responses showed an influence on the early viral set point, a broader HIV-specific CD8 T cell response targeting epitopes within HIV-1 Gag during primary HIV-1 infection was associated with slower disease progression. Moreover, the induction of certain HIV-specific CD8 T cell responses--but not others--significantly influenced the time to ART initiation. Individual epitope-specific CD8 T cell responses contribute significantly to HIV-1 disease control, demonstrating that the specificity of the initial HIV-specific CD8 T cell response rather than the restricting HLA class I molecule alone is a critical determinant of antiviral function. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
27. New Subtype B Containing HIV-1 Circulating Recombinant of sub-Saharan Africa Origin in Nigerian Men Who Have Sex With Men.
- Author
-
Billings E, Kijak GH, Sanders-Buell E, Ndembi N, OʼSullivan AM, Adebajo S, Kokogho A, Milazzo M, Lombardi K, Baral S, Nowak R, Ramadhani H, Gramzinski R, Robb ML, Michael NL, Charurat ME, Ake J, Crowell TA, and Tovanabutra S
- Subjects
- Adult, Bayes Theorem, France, Genome, Viral, HIV Infections epidemiology, HIV Infections transmission, Humans, Male, Molecular Epidemiology, Nigeria, Prevalence, Prospective Studies, Young Adult, HIV Infections virology, HIV-1 classification, HIV-1 genetics, Homosexuality, Male, Phylogeny, Recombination, Genetic, Sexual and Gender Minorities
- Abstract
Background: HIV-1 circulating recombinant forms (CRF) containing subtype B are uncommon in sub-Saharan Africa. Prevalent infections observed during enrollment of a prospective study of men who have sex with men (MSM) from Lagos, Nigeria, revealed the presence of a family of subtype B and CRF02_AG recombinants. This report describes the HIV-1 genetic diversity within a high-risk, high-prevalence, and previously undersampled cohort of Nigerian MSM., Methods: Between 2013 and 2016, 672 MSM were enrolled at the Lagos site of the TRUST/RV368 study. Prevalent HIV-1 infections were initially characterized by pol sequencing and phylogenetic subtyping analysis. Samples demonstrating the presence of subtype B were further characterized by near full-length sequencing, phylogenetic, and Bayesian analyses., Results: Within this cohort, HIV-1 prevalence was 59%. The major subtype was CRF02_AG (57%), followed by CRF02/B recombinants (15%), subtype G (13%), and smaller amounts of A1, B, and other recombinants. Nine clusters of closely related pol sequences indicate ongoing transmission events within this cohort. Among the CRF02_AG/B, a new CRF was identified and termed CRF95_02B. Shared risk factors and Bayesian phylogenetic inference of the new CRF95_02B and the similarly structured CRF56_cpx indicate a Nigerian or West African origin of CRF56_cpx before its observation in France., Conclusion: With high HIV-1 prevalence, new strains, and multiple transmission networks, this cohort of Nigerian MSM represents a previously hidden reservoir of HIV-1 strains, including the newly identified CRF95_02B and closely related CRF56_cpx. These strains will need to be considered during vaccine selection and development to optimize the design of a globally effective HIV-1 vaccine.
- Published
- 2019
- Full Text
- View/download PDF
28. Evaluation of Performance of Two Rapid Tests for Detection of HIV-1 and -2 in High- and Low-Prevalence Populations in Nigeria.
- Author
-
Manak MM, Njoku OS, Shutt A, Malia J, Jagodzinski LL, Milazzo M, Suleiman A, Ogundeji AA, Nelson R, Ayemoba OR, O'Connell RJ, Singer DE, Michael NL, and Peel SA
- Subjects
- AIDS Vaccines therapeutic use, False Negative Reactions, False Positive Reactions, Female, HIV Antibodies, HIV-1 genetics, HIV-2 genetics, Humans, Nigeria epidemiology, RNA, Viral analysis, RNA, Viral genetics, Sensitivity and Specificity, Diagnostic Tests, Routine methods, HIV Infections diagnosis, HIV Infections epidemiology, HIV-1 immunology, HIV-2 immunology, Immunoassay methods
- Abstract
The availability of reliable human immunodeficiency virus types 1 and 2 (HIV-1/2) rapid tests in resource-limited settings represents an important advancement in the accurate diagnosis of HIV infection and presents opportunities for implementation of effective prevention and treatment interventions among vulnerable populations. A study of the potential target populations for future HIV vaccine studies examined the prevalence of HIV infections at six selected sites in Nigeria and evaluated the use of two rapid diagnostic tests (RDTs) for HIV. The populations included market workers at sites adjacent to military installations and workers at highway settlements (truck stops) who may have a heightened risk of HIV exposure. Samples from 3,187 individuals who provided informed consent were tested in parallel using the Determine (DT) and Stat-Pak (SP) RDTs; discordant results were subjected to the Uni-Gold (UG) RDT as a tiebreaker. The results were compared to those of a third-generation enzyme immunoassay screen with confirmation of repeat reactive samples by HIV-1 Western blotting. One participant was HIV-2 infected, yielding positive results on both RDTs. Using the laboratory algorithm as a gold standard, we calculated sensitivities of 98.5% (confidence interval [CI], 97.1 to 99.8%) for DT and 98.1% (CI, 96.7 to 99.6%) for SP and specificities of 98.7% (CI, 98.3 -99.1%) for DT and 99.8% (CI, 99.6 to 100%) for SP. Similar results were obtained when the sites were stratified into those of higher HIV prevalence (9.4% to 22.8%) versus those of lower prevalence (3.2% to 7.3%). A parallel two-test algorithm requiring both DT and SP to be positive resulted in the highest sensitivity (98.1%; CI, 96.7 to 99.6%) and specificity (99.97%; CI, 99.9 to 100%) relative to those for the reference laboratory algorithm., (Copyright © 2015, Manak et al.)
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.